Prof.ssa Olga Lamacchia

Endocrinologa, Diabetologa Altro

Foggia 1 indirizzo

Mostra contatti

Esperienze

Aree di competenza principali:

  • Diabetologia
  • Endocrinologia

Principali patologie trattate

Esperienze

Doctor
Olga Lamacchia

endocrinologo, diabetologo

Patologie trattate

Mostra dettagli

Pubblicazioni

  • HypoparaNet: A Database of Chronic Hypoparathyroidism Based on Expert Medical-Surgical Centers in Italy. Marcucci G, Cianferotti L, Parri S, Altieri P, Arvat E, Benvenga S, Betterle C, Bondanelli M, Boscaro M, Camozzi V, Centaro GM, Cetani F, Chiodini I, Ciampolillo A, Colao A, Corbetta S, De Feo ML, Uberti ED, Faggiano A, Fornari R, Gaspari AL, Giorgino F, Giuliani V, Iacobone M, Innaro N, Lamacchia O, Lenzi A, Mantovani G, Marcocci C, Masi L, Migliaccio S, Palmieri S, Pasquali R, Perigli G, Piccini V, Romagnoli E, Ruggeri RM, Rulli F, Samà MT, Tomaino G, Trimarchi F, Zatelli MC, Brandi ML. Calcif Tissue Int. 2018 Mar 6. doi: 018-0411-7.
  • Metabolic control and complications in Italian people with diabetes treated with continuous subcutaneous insulin infusion. Lepore G, Bonfanti R, Bozzetto L, Di Blasi V, Girelli A, Grassi G, Iafusco D, Laviola L, Rabbone I, Schiaffini R, Bruttomesso D; Italian Study Group on the Diffusion of CSII. Nutr Metab Cardiovasc Dis. 2018 Apr;28(4):335-342. doi: 10.1016/j.numecd .
  • Rationale and design of the DARWIN-T2D (DApagliflozin Real World evIdeNce in Type 2 Diabetes): A multicenter retrospective nationwide Italian study and crowdsourcing opportunity. Fadini GP, Zatti G, Consoli A, Bonora E, Sesti G, Avogaro A; DARWINT2D Network. Nutr Metab Cardiovasc Dis. 2017 Dec;27(12):1089-1097. doi: 10.1016/j.numecd
  • Pharmacogenetics of oral antidiabetes drugs: evidence for diverse signals at the IRS1 locus. Prudente S, Di Paola R, Pezzilli S, Garofolo M, Lamacchia O, Filardi T, Mannino GC, Mercuri L, Alberico F, Scarale MG, Sesti G, Morano S, Penno G, Cignarelli M, Copetti M, Trischitta V. Pharmacogenomics J. 2017 Jul 11. doi: 10.1038/tpj.2017.32. [Epub ahead of print]
  • Glucose targets for preventing diabetic kidney disease and its progression. Ruospo M, Saglimbene VM, Palmer SC, De Cosmo S, Pacilli A, Lamacchia O, Cignarelli M, Fioretto P, Vecchio M, Craig JC, Strippoli GF. Cochrane Database Syst Rev. 2017 Jun 8;6:CD010137. doi: CD010137.pub2. Review.
  • On the non-linear association between serum uric acid levels and all-cause mortality rate in patients with type 2 diabetes mellitus. Lamacchia O, Fontana A, Pacilli A, Copetti M, Fariello S, Garofolo M, Penno G, Trischitta V, De Cosmo S, Cignarelli M. Atherosclerosis. 2017 May;260:20-26. doi: 10.1016/j.atherosclerosis.2017.03.008. Epub 2017 Mar 9.
  • Serum resistin is causally related to mortality risk in patients with type 2 diabetes: preliminary evidences from genetic data. Fontana A, Ortega Moreno L, Lamacchia O, De Bonis C, Salvemini L, De Cosmo S, Cignarelli M, Copetti M, Trischitta V, Menzaghi C. Sci Rep. 2017 Mar 3;7(1):61. doi: 10.1038/s41598-017-00138-3.
  • The PPARγ2 P12A polymorphism is not associated with all-cause mortality in patients with type 2 diabetes mellitus. Pacilli A, Prudente S, Copetti M, Fontana A, Mercuri L, Bacci S, Marucci A, Alberico F, Viti R, Palena A, Lamacchia O, Cignarelli M, De Cosmo S, Trischitta V. Endocrine. 2016 Oct;54(1):38-46. Epub 2016 Mar 8.
  • The rs12917707 polymorphism at the UMOD locus and glomerular filtration rate in individuals with type 2 diabetes: evidence of heterogeneity across two different European populations.
  • TRAP1 regulates cell cycle and apoptosis in thyroid carcinoma cells. Palladino G, Notarangelo T, Pannone G, Piscazzi A, Lamacchia O, Sisinni L, Spagnoletti G, Toti P, Santoro A, Storto G, Bufo P, Cignarelli M, Esposito F, Landriscina M. Endocr Relat Cancer. 2016 Sep;23(9):699-709. doi: 10.1530/ERC-16-0063. Epub 2016 Jul 15.
  • The combined effect of adiponectin and resistin on all-cause mortality in patients with type 2 diabetes: Evidence of synergism with abdominal adiposity. Ortega Moreno L, Lamacchia O, Fontana A, Copetti M, Salvemini L, De Bonis C, Cignarelli M, Trischitta V, Menzaghi C. Atherosclerosis. 2016 Jul;250:23-9. doi: 10.1016/j.atherosclerosis.2016.04.028. Epub 2016 Apr 27.
  • The PPARγ2 P12A polymorphism is not associated with all-cause mortality in patients with type 2 diabetes mellitus. Pacilli A, Prudente S, Copetti M, Fontana A, Mercuri L, Bacci S, Marucci A, Alberico F, Viti R, Palena A, Lamacchia O, Cignarelli M, De Cosmo S, Trischitta V. Endocrine. 2016 Mar 8. [Epub ahead of print]
  • The paradoxical association of adiponectin with mortality rate in patients with type 2 diabetes: evidence of synergism with kidney function. Ortega Moreno L, Lamacchia O, Salvemini L, De Bonis C, De Cosmo S, Cignarelli M, Trischitta V, Menzaghi C. Atherosclerosis. 2016 Feb;245:222-7. doi: 10.1016/j.atherosclerosis Epub 2015 Dec 22.
  • RAS/BRAF mutational status in familial non-medullary thyroid carcinomas: A retrospective study. Landriscina M, Natalicchio MI, Lamacchia O, Conserva A, Piscazzi A, Ciampolillo A, Zingrillo M, Pennella A, Bufo P, Vita G, Antonetti R, Maiorano E, Giorgino F, Cignarelli M. Oncol Lett. 2015 Sep;10(3):1875-1881. Epub 2015 Jun 17.
  • Serum Adiponectin and Glomerular Filtration Rate in Patients with Type 2 Diabetes. Ortega Moreno L, Lamacchia O, Copetti M, Salvemini L, De Bonis C, De Cosmo S, Cignarelli M, Trischitta V, Menzaghi C. PLoS One. 2015 Oct 14;10(10):e0140631. doi: 10.1371/journal.pone.0140631. eCollection 2015.
  • Independent correlates of urinary albumin excretion within the normoalbuminuric range in patients with type 2 diabetes: The Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicentre Study. Penno G, Solini A, Zoppini G, Fondelli C, Trevisan R, Vedovato M, Cavalot F, Gruden G, Lamacchia O, Laviola L, Orsi E, Pugliese G; Renal Insufficiency Cardiovascular Events (RIACE) Study Group.Acta Diabetol. 2015 Oct;52(5):971-81. doi: 015-0789-x. Epub 2015 Jul 10.
  • Hypertriglyceridemia Is Independently Associated with Renal, but Not Retinal Complications in Subjects with Type 2 Diabetes: A Cross-Sectional Analysis of the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study. Penno G, Solini A, Zoppini G, Fondelli C, Trevisan R, Vedovato M, Gruden G, Lamacchia O, Pontiroli AE, Arosio M, Orsi E, Pugliese G; Renal Insufficiency And Cardiovascular Events (RIACE) Study Group.PLoS One. 2015 May 5;10(5):e0125512. doi: 10.1371/journal.pone.0125512. eCollection 2015
  • Target values of cardiovascular risk factors are not associated with all-cause mortality in patients with type 2 diabetes mellitus. Pacilli A, Lamacchia O, Fontana A, Copetti M, Cignarelli M, Trischitta V, De Cosmo S. PLoS One. 2015 Apr 30;10(4):e0124536. doi: 10.1371/journal.pone.0124536. eCollection 2015.
  • Continuous subcutaneous insulin infusion in Italy: third national survey. Bruttomesso D, Laviola L, Lepore G, Bonfanti R, Bozzetto L, Corsi A, Di Blasi V, Girelli A, Grassi G, Iafusco D, Rabbone I, Schiaffini R; Italian Study Group on Diffusion of CSII. Diabetes Technol Ther. 2015 Feb;17(2):96-104. doi: 10.1089/dia.2014.0242. Epub 2014 Dec 5.
  • Mitotane and Carney Complex: ten years follow-up of a low-dose mitotane regimen inducing a sustained correction of hypercortisolism. Campo MR, Lamacchia O, Farese A, Conserva A, Picca G, Grilli G, Cignarelli M. Hormones (Athens). 2014 Nov 5.
  • A novel mutation in calcium-sensing receptor gene associated to hypercalcemia and hypercalciuria. Mastromatteo E, Lamacchia O, Campo MR, Conserva A, Baorda F, Cinque L, Guarnieri V, Scillitani A, Cignarelli M. BMC Endocr Disord. 2014 Oct 7;14:81
  • Resistant hypertension in patients with type 2 diabetes: clinical correlates and association with complications. Solini A, Zoppini G, Orsi E, Fondelli C, Trevisan R, Vedovato M, Cavalot F, Lamacchia O, Arosio M, Baroni MG, Penno G, Pugliese G; Renal Insufficiency And Cardiovascular Events (RIACE) Study Group. J Hypertens. 2014 Dec;32(12):2401-10
  • IRS1 G972R missense polymorphism is associated with failure to oral antidiabetes drugs in white patients with type 2 diabetes from Italy. Prudente S, Morini E, Lucchesi D, Lamacchia O, Bailetti D, Mercuri L, Alberico F, Copetti M, Pucci L, Fariello S, Giusti L, Cignarelli M, Penno G, De Cosmo S, Trischitta V.Diabetes 2014 Sep;63(9):3135-40. doi: 10.2337/db13-1966. Epub 2014 Jun 19.
  • Chronic kidney disease in type 2 diabetes: lessons from the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicentre Study.Pugliese G, Solini A, Bonora E, Fondelli C, Orsi E, Nicolucci A, Penno G; RIACE Study Group. Nutr Metab Cardiovasc Dis. 2014 Aug;24(8):815-22. doi: 10.1016/j.numecd.2014.02.013. Epub 2014 Mar 1..
  • Distribution of cardiovascular disease and retinopathy in patients with type 2 diabetes according to different classification systems for chronic kidney disease: a cross-sectional analysis of the renal insufficiency and cardiovascular events (RIACE) Italian multicenter study. Pugliese G, Solini A, Bonora E, Orsi E, Zerbini G, Fondelli C, Gruden G, Cavalot F, Lamacchia O, Trevisan R, Vedovato M, Penno G; RIACE Study Group.Cardiovasc Diabetol. 2014 Mar 13;13:59. doi: -1359.
  • Normoalbuminuric renal impairment and all-cause mortality in type 2 diabetes mellitus.De Cosmo S, Lamacchia O, Pacilli A, Fariello S, Pinnelli S, Fontana A, Di Mauro L, Cignarelli M, Trischitta V. Acta Diabetol. 2014 Aug;51(4):687-9. doi: 014-0577-z. Epub 2014 Mar 13. No abstract available.
  • Hemoglobin A1c variability as an independent correlate of cardiovascular disease in patients with type 2 diabetes a crosssectional analysis of the Renal Insufficiency and Cardiovascular Events (RIACE) Italian Multicenter Study. Penno G, Solini A, Zoppini G, Orsi E, Fondelli C, Zerbini G, Morano S, Cavalot F, Lamacchia O, Trevisan R, Vedovato M, Pugliese G. Cardiovasc Diabetol. 2013 Jul 5;12(1):98. [Epub ahead of print]
  • Development and Validation of a Predicting Model of All-Cause Mortality in Patients With Type 2 Diabetes Mellitus. De Cosmo S, Copetti M, Lamacchia O, Fontana A, Massa M, Morini E, Pacilli A, Fariello S, Palena A, Rauseo A, Viti R, Di Paola R, Menzaghi C, Cignarelli M, Pellegrini F, Trischitta V. Diabetes Care. 2013 May 1. [Epub ahead of print]
  • HbA1c Variability As an Independent Correlate of Nephropathy, but Not Retinopathy, in Patients With Type 2 Diabetes: The Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study. Penno G, Solini A, Bonora E, Fondelli C, Orsi E, Zerbini G, Morano S, Cavalot F, Lamacchia O, Laviola L, Nicolucci A, Pugliese G; for the Renal Insufficiency And Cardiovascular Events (RIACE) Study Group. Diabetes Care. 2013 Mar 14. [Epub ahead of print]
  • High prevalence of advanced retinopathy in patients with type 2 diabetes from the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study. Pugliese G, Solini A, Zoppini G, Fondelli C, Zerbini G, Vedovato M, Cavalot F, Lamacchia O, Buzzetti R, Morano S, Nicolucci A, Penno G; Renal Insufficiency and Cardiovascular Events (RIACE) Study Group. Diabetes Res Clin Pract. 2012 Nov;98(2):329-37.
  • Clinical significance of nonalbuminuric renal impairment in type 2 diabetes. Penno G, Solini A, Bonora E, Fondelli C, Orsi E, Zerbini G, Trevisan R, Vedovato M, Gruden G, Cavalot F, Cignarelli M, Laviola L, Morano S, Nicolucci A, Pugliese G; Renal Insufficiency And Cardiovascular Events (RIACE) Study Group. J Hypertens. 2011 Sep;29(9):1802-9.
  • PPAR{gamma}2 P12A polymorphism and albuminuria in patients with type 2 diabetes: a meta-analysis of case-control studies. De Cosmo S, Prudente S, Lamacchia O, Lapice E, Morini E, Di Paola R, Copetti M, Ruggenenti P, Remuzzi G, Vaccaro O, Cignarelli M, Trischitta V. Nephrol Dial Transplant. 2011 Apr 14. [Epub ahead of print]
  • Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials. Maione A, Navaneethan SD, Graziano G, Mitchell R, Johnson D, Mann JF, Gao P, Craig JC, Tognoni G, Perkovic V, Nicolucci A, De Cosmo S, Sasso A, Lamacchia O, Cignarelli M, Maria Manfreda V, Gentile G, Strippoli GF. Nephrol Dial Transplant. 2011 Sep;26(9):282747. Epub 2011 Mar 3.
  • Urine proteome analysis may allow noninvasive differential diagnosis of diabetic nephropathy. Papale M, Di Paolo S, Magistroni R, Lamacchia O, Di Palma AM, De Mattia A, Rocchetti MT, Furci L, Pasquali S, De Cosmo S, Cignarelli M, Gesualdo L. Diabetes Care. 2010 Nov;33(11):2409-15. Epub 2010 Jul 29.
  • Para- and perirenal fat thickness is an independent predictor of chronic kidney disease, increased renal resistance index and hyperuricaemia in type-2 diabetic patients. Lamacchia O, Nicastro V, Camarchio D, Valente U, Grisorio R, Gesualdo L, Cignarelli M. Nephrol Dial Transplant. 2010 Aug 26. [Epub ahead of print]
  • Increased cardiovascular risk among type 2 diabetic patients with high-normal albuminuria and no evidence of kidney impairment. Cignarelli M, Lamacchia O, Gesualdo L, Pilotti A, Pacilli A, Santini SA, De Cosmo S. Nutr Metab Cardiovasc Dis. 2010 Sep 25.
  • Erlotinib enhances the proapoptotic activity of cytotoxic agents and synergizes with paclitaxel in poorly-differentiated thyroid carcinoma cells. Landriscina M, Maddalena F, Fabiano A, Piscazzi A, Lamacchia O, Cignarelli M. Anticancer Res. 2010 Feb;30(2):473-80.
  • Metabolic syndrome and albuminuria show an additive effect in modulating glomerular filtration rate in patients with Type 2 Diabetes Mellitus. Mauro Cignarelli, Olga Lamacchia, Giada Cardinale, Anna Rauseo, Sandra Mastroianno, Loreto Gesualdo, Salvatore De Cosmo. Diabetes and Metabolic Syndrome: Clinical Research and Reviews. 20093(3):139-142
  • Waist-to-height ratio is the best anthropometric index in association with adverse cardiorenal outcomes in Type 2 Diabetes Mellitus patients. O. Lamacchia, S. Pinnelli, D. Camarchio, S. Fariello, L. Gesualdo, G. Stallone, M. Cignarelli Am J Nephrol. 2009 29(6):615-619 (IF: 2.658)
  • Fitness, fatness, and chronic kidney disease. Response M. Cignarelli, O. Lamacchia. Nutr Metab Cardiovasc Dis. 2008 18(4):e13; author reply e15.
  • Development and validation of a fast quantitative method for plasma dimethylarginines analysis using liquid chromatographytandem mass spectrometry. D'Apolito O, Paglia G, Tricarico F, Garofalo D, Pilotti A, Lamacchia O, Cignarelli M, Corso G. Clin Biochem. 2008 Nov;41(16-17):1391-5.
  • L. Gesualdo, G. Stallone, B. Infante, A. Di Palma, P. Delli Carri, M. Cignarelli, O. Lamacchia, S. Iannaccone, S. Di Paolo, L. Morrone, F. Aucella, G. Carrieri, L. Cormio. Percutaneous Ultrasound - Guided Renal Biopsy in supine Antero-Lateral Position. A New Approach for Obese and Non Obese Patients. Nephrology Dialysis Transplantation 2008 Mar;23(3):971-6.
  • O. Lamacchia ^, V. Nicastro ^, D. Camarchio, G. Stallone, L. Gesualdo, M. Cignarelli. Waist Circumference is strongly Associated with Renal Resistive Index in Normoalbuminuric Patients with Type 2 Diabetes. ^These two authors equal ly contributed to this work. American Journal of Nephrology 2008;28(1):54-8.
  • M. Cignarelli, O. Lamacchia, S. Di Paolo, L. Gesualdo. Cigarette Smoking and Kidney Dysfunction in Diabetes Mellitus. Journal of Nephrology 2008 Mar-Apr;21(2):180-9. Review.
  • M. Cignarelli, O. Lamacchia. Obesity and Kidney disease. Review. Nutr Metab Cardiovasc Dis. 2007 Dec;17(10):757-62.
  • S. De Cosmo, O. Lamacchia, L. Gesualdo,V. Trischitta, M. Cignarelli. Cigarette Smoking is Associated with Low Glomerular Filtration Rate in Male Patients with Type 2 Diabetes: Response to Saito et al. Diabetes Care, 30(3):e3, 2007
  • M. Cignarelli, A. Ambrosi, A. Marino, O. Lamacchia, M. Campo, G. Picca, F. Giorgino. Diagnostic utility of Thyroglobulin Detection in Fine-Needle Aspiration of Cervical Cystic Metastatic Lymph Nodes from Papillary Thyroid Cancer with Negative Cytology Thyroid (13)12:1163-1167, 2003
  • M. Cignarelli, A. Ambrosi, A. Marino, O. Lamacchia, R. Cincione, V. Neri. Three cases of papillary carcinoma and three of adenoma in thyroglossal duct cysts: Clinical - diagnostic comparison with benign thyroglossal duct cysts. J Endocrinol Invest. 25: 947-954, 2002
Mostra dettagli

Formazione

  • Università degli Studi di Foggia

Premi e riconoscimenti

  • Componente del Comitato Ordinatore della Scuola di Specializzazione di Area Sanitaria in “Endocrinologia e Malattie del Metabolismo”della sede di Foggia (Scuola di Specializzazione aggregata all’Università degli Studi di Bari). dal 01-01-2009 a oggi
  • Delegata del Dipartimento di Scienze Mediche e Chirurgiche dell'Università degli Studi di Foggia all’Orientamento e al Tutorato dal 03-08-2012 al 01-12-2013
  • Componente della Commissione Didattica Paritetica del Dipartimento di Scienze Mediche e Chirurgiche dell'Università degli Studi di Foggia dal 10-12-2012 a oggi
  • Componente eletta rappresentante dei ricercatori di area medica nel Senato Accademico dell’Università degli Studi di Foggia dal 06-11-2015 a oggi
Prenota una visita

Indirizzo

Vedi mappa si apre in una nuova scheda
Studio medico specialistico di Endocrinologia/Diabetologia e malattie del metabolismo della Prof.ssa Olga Lamacchia

Via Filippo Buonarota, 13, Foggia 71122

Disponibilità

Questo dottore non offre prenotazioni online a questo indirizzo

Pazienti accettati

  • Pazienti senza assicurazione sanitaria
Vedi mappa si apre in una nuova scheda

Dettagli dell'indirizzo

Modalità di pagamento (visite private)
  • Contanti
  • Carta di credito
  • Carta di debito
  • Bonifico istantaneo
Prestazioni disponibili

Prestazioni disponibili

Studio medico specialistico di Endocrinologia/Diabetologia e malattie del metabolismo della Prof.ssa Olga Lamacchia

Prestazioni e prezzi

  • Visita endocrinologica

  • Ecografia

  • Prima Visita

  • Visita di controllo

Recensioni in arrivo

Scrivi la prima recensione

Hai avuto una visita con Prof.ssa Olga Lamacchia? Condividi quello che pensi. Grazie alla tua esperienza gli altri pazienti potranno scegliere il miglior dottore per loro.

Aggiungi una recensione
Città vicino Foggia
Principali patologie trattate

E' necessario il pagamento della tua visita

Il dottore con cui hai prenotato richiede di effettuare il pagamento. Per riprogrammare il tuo appuntamento, procedi con il pagamento oppure contatta direttamente il dottore.
Le mie visite Paga